DMD and Duchenne muscular dystrophy: The first in vivo demonstration of the therapeutic AAG properties has been in mdx mice, an animal model of Duchenne muscular dystrophy (DMD), where gentamicin treatment restored 10–20% of normal dystrophin levels in the skeletal muscles (Barton-Davis et al., 1999).